Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Buy
80
MCK Quote, Financials, Valuation and Earnings
Last price:
$716.61
Seasonality move
:
9.33%
Day range:
$675.08 - $695.46
52-week range:
$464.42 - $695.46
Dividend yield:
0.4%
P/E ratio:
31.76x
P/S ratio:
0.26x
P/B ratio:
--
Volume:
1.2M
Avg. volume:
914.6K
1-year change:
30.05%
Market cap:
$86.9B
Revenue:
$309B
EPS (TTM):
$21.84
Analysts' Opinion
-
Consensus RatingMcKesson has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $678.85, McKesson has an estimated downside of -2.12% from its current price of $693.53.
-
Price Target UpsideAccording to analysts, the highest upside price target is $745.00 representing 7.42% upside increase from its current price of $693.53.
Fair Value
-
According to the consensus of 13 analysts, McKesson has -2.12% downside to fair value with a price target of $678.85 per share.
MCK vs. S&P 500
-
Over the past 5 trading days, McKesson has overperformed the S&P 500 by 2.94% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
McKesson does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
McKesson has grown year-over-year revenues for 18 quarters straight. In the most recent quarter McKesson reported revenues of $95.3B.
Earnings Growth
-
McKesson has grown year-over-year earnings for 1 quarter straight. In the most recent quarter McKesson reported earnings per share of $6.95.
Enterprise value:
94.2B
EV / Invested capital:
--
Price / LTM sales:
0.26x
EV / EBIT:
21.83x
EV / Revenue:
0.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
57.64x
Price / Operating cash flow:
55.00x
Enterprise value / EBITDA:
18.99x
Gross Profit (TTM):
$13.3B
Return On Assets:
4.05%
Net Income Margin (TTM):
0.82%
Return On Equity:
--
Return On Invested Capital:
67.6%
Operating Margin:
1.32%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $273.9B | $301.5B | $344.6B | $80.9B | $95.3B | |
| Gross Profit | $12.6B | $12.3B | $13.3B | $3.2B | $3.3B | |
| Operating Income | $4.3B | $3.9B | $4.5B | $646M | $1.3B | |
| EBITDA | $5.2B | $4.4B | $5B | $835M | $1.4B | |
| Diluted EPS | $21.81 | $22.07 | $21.84 | $4.42 | $6.95 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $42.4B | $46.5B | $44.7B | $47.6B | $51.7B | |
| Total Assets | $61.8B | $63.7B | $62.7B | $66.5B | $71.1B | |
| Current Liabilities | $41.9B | $47.5B | $48B | $51.7B | $58.6B | |
| Total Liabilities | $60.8B | $64.5B | $64.8B | $68.2B | $73.8B | |
| Total Equity | $1B | -$787M | -$2.1B | -$1.7B | -$2.7B | |
| Total Debt | $7.4B | $6.3B | $6.5B | $5.9B | $8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $4.7B | $3.5B | $2.5B | $254M | -$2.4B | |
| Cash From Investing | -$115M | -$739M | -$1.1B | -$180M | -$136M | |
| Cash From Financing | -$5.2B | -$3.6B | -$2.1B | -$622M | $1.3B | |
| Free Cash Flow | $4.2B | $2.9B | $1.6B | $100M | -$2.6B | |
MCK
Sector
Market Cap
$86.9B
$35.9M
Price % of 52-Week High
99.72%
43.21%
Dividend Yield
0.4%
0%
Shareholder Yield
4.54%
-0.91%
1-Year Price Total Return
30.05%
-43.29%
Beta (5-Year)
0.494
0.746
Dividend yield:
0.4%
Annualized payout:
$2.40
Payout ratio:
11.89%
Growth streak:
11 years
Technicals
8-day SMA
Buy
Level
$670.18
200-day SMA
Buy
Level
$579.61
Bollinger Bands (100)
Buy
Level
577.27 - 642.29
Chaikin Money Flow
Buy
Level
366.7M
20-day SMA
Buy
Level
$659.16
Relative Strength Index (RSI14)
Buy
Level
78.42
ADX Line
Buy
Level
25.82
Williams %R
Sell
Level
-3.4287
50-day SMA
Buy
Level
$627.17
MACD (12, 26)
Buy
Level
14.93
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
256.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.6199)
Sell
CA Score
(Annual)
Level (-0.742)
Buy
Beneish M-Score
(Annual)
Level (-2.4055)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.1596)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Stock Forecast FAQ
In the current month, MCK has received 10 Buy ratings 3 Hold ratings, and 0 Sell ratings. The MCK average analyst price target in the past 3 months is $678.85.
-
Where Will McKesson Stock Be In 1 Year?
According to analysts, the consensus estimate is that McKesson share price will drop to $678.85 per share over the next 12 months.
-
What Do Analysts Say About McKesson?
Analysts are divided on their view about McKesson share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that McKesson is a Sell and believe this share price will rise from its current level to $550.00.
-
What Is McKesson's Price Target?
The price target for McKesson over the next 1-year time period is forecast to be $678.85 according to 13 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is MCK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for McKesson is a Buy. 10 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MCK?
You can purchase shares of McKesson via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase McKesson shares.
-
What Is The McKesson Share Price Today?
McKesson was last trading at $716.61 per share. This represents the most recent stock quote for McKesson. Yesterday, McKesson closed at $693.53 per share.
-
How To Buy McKesson Stock Online?
In order to purchase McKesson stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
43
MNPR alert for Apr 3
Monopar Therapeutics [MNPR] is down 10.04% over the past day.
Buy
75
BKTI alert for Apr 3
BK Technologies [BKTI] is down 7.68% over the past day.
Sell
34
SWTX alert for Apr 3
SpringWorks Therapeutics [SWTX] is down 7.29% over the past day.
